Multivalent Aptamer‐Based Lysosome‐Targeting Chimeras (LYTACs) Platform for Mono‐ or Dual‐Targeted Proteins Degradation on Cell Surface
Advanced Science · 2024-05 · 11 (17)
DOI: 10.1002/advs.202308924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 29.02.2024. Verfasst von Qiao Duan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Medicine (IMM), Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University, Shanghai, 200…. Hauptthemen laut MEDLINE: Lysosomes, Aptamers, Nucleotide, Proteolysis. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Research Center for Diagnosis and Treatment of Major Diseases, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Selective protein degradation platforms have opened novel avenues in therapeutic development and biological inquiry. Antibody‐based lysosome‐targeting chimeras (LYTACs) have emerged as a promising technology that extends the scope of targeted protein degradation to extracellular targets. Aptamers offer an advantageous alternative owing to their potential for modification and manipulation toward a multivalent state. In this study, a chemically engineered platform of multivalent aptamer‐based LYTACs (AptLYTACs) is established for the targeted degradation of either single or dual protein targets. Leveraging the biotin‐streptavidin system as a molecular scaffold, this investigation reveals that trivalently mono‐targeted AptLYTACs demonstrate optimum efficiency in degrading membrane proteins. The development of this multivalent AptLYTACs platform provides a principle of concept for mono‐/dual‐targets degradation, expanding the possibilities of targeted protein degradation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Medicine (IMM), Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University, Shanghai, 200120, China.
- Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
- Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410006, China.
ORCID-Profile: Qiao Duan, Weihong Tan
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Research Center for Diagnosis and Treatment of Major Diseases
- China Postdoctoral Science Foundation
- Instrumentation Core Facility at the Institute of Basic Medicine and Cancer
- Chinese Academy of Sciences
- National Postdoctoral Program for Innovative Talents
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Duan, Q., Jia, H. R., Chen, W., Qin, C., Zhang, K., Jia, F., Fu, T., Wei, Y., Fan, M., Wu, Q., & Tan, W. (2024). Multivalent Aptamer‐Based Lysosome‐Targeting Chimeras (LYTACs) Platform for Mono‐ or Dual‐Targeted Proteins Degradation on Cell Surface. Advanced Science, 11(17). https://doi.org/10.1002/advs.202308924
Vancouver
Duan Q, Jia HR, Chen W, Qin C, Zhang K, Jia F, et al. Multivalent Aptamer‐Based Lysosome‐Targeting Chimeras (LYTACs) Platform for Mono‐ or Dual‐Targeted Proteins Degradation on Cell Surface. Advanced Science. 2024;11(17). doi:10.1002/advs.202308924
BibTeX
@article{Duan2024,
author = {Duan, Qiao and Jia, Hao-Ran and Chen, Weichang and Qin, Chunhong and Zhang, Kejing and Jia, Fei and Fu, Ting and Wei, Yong and Fan, Mengyang and Wu, Qin and Tan, Weihong},
title = {Multivalent Aptamer‐Based Lysosome‐Targeting Chimeras (LYTACs) Platform for Mono‐ or Dual‐Targeted Proteins Degradation on Cell Surface},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {17},
doi = {10.1002/advs.202308924}
}
EUVIMED